Purpose of this Study
We are doing this study to find out if continued use of an experimental drug called bomedemstat (the study drug) can provide an extended benefit for people with myeloproliferative neoplasms. We are enrolling people who have been in a previous study using the study drug and received a positive benefit.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with thrombocythemia, polycythemia vera, or myelofibrosis
- Participated in a previous clinical trial using bomedemstat (participants from the IMG-7289-202/MK-3543-005 study must have received at least 6 months of treatment with the study drug)
- Do not have a history of noncompliance in a prior bomedemstat study
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
You can choose to join this study when you finish your current/previous trial of the study drug. If you are interested in joining, the study doctor will assess your eligibility at the end of your original bomedemstat trial and transition you into this study at its end if you are eligible to continue taking the study drug.
You will visit our clinic roughly every 4 weeks while you take the study drug in this trial. You will remain in the study for as long as you and your doctor believe that you are getting a positive benefit.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Multicenter, Open-Label, Extension Study Evaluating the Safety and
Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Principal Investigator
Lindsay
Rein
Protocol Number
PRO00116787
NCT ID
NCT06351631
Phase
III
Enrollment Status
Pending Open to Enrollment